Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Long-Term Investments (2016 - 2026)

United Therapeutics' Long-Term Investments history spans 17 years, with the latest figure at $1.8 billion for Q4 2025.

  • On a quarterly basis, Long-Term Investments rose 20.43% to $1.8 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.8 billion, a 20.43% increase, with the full-year FY2025 number at $1.8 billion, up 20.43% from a year prior.
  • Long-Term Investments hit $1.8 billion in Q4 2025 for United Therapeutics, up from $1.6 billion in the prior quarter.
  • Over the last five years, Long-Term Investments for UTHR hit a ceiling of $2.1 billion in Q3 2023 and a floor of $1.3 billion in Q3 2024.
  • Historically, Long-Term Investments has averaged $1.6 billion across 5 years, with a median of $1.6 billion in 2022.
  • Biggest five-year swings in Long-Term Investments: surged 65.15% in 2021 and later plummeted 37.92% in 2024.
  • Tracing UTHR's Long-Term Investments over 5 years: stood at $1.6 billion in 2021, then fell by 20.23% to $1.3 billion in 2022, then surged by 45.1% to $1.9 billion in 2023, then decreased by 22.75% to $1.5 billion in 2024, then rose by 20.43% to $1.8 billion in 2025.
  • Business Quant data shows Long-Term Investments for UTHR at $1.8 billion in Q4 2025, $1.6 billion in Q3 2025, and $1.9 billion in Q2 2025.